Mengis Capital Management Inc. increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 46.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,225 shares of the biopharmaceutical company’s stock after buying an additional 705 shares during the period. Mengis Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,092,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Morse Asset Management Inc raised its position in Regeneron Pharmaceuticals by 8.1% in the second quarter. Morse Asset Management Inc now owns 9,307 shares of the biopharmaceutical company’s stock valued at $4,571,000 after buying an additional 700 shares during the last quarter. Kelly Lawrence W & Associates Inc. CA raised its position in Regeneron Pharmaceuticals by 2.8% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 25,220 shares of the biopharmaceutical company’s stock valued at $12,386,000 after buying an additional 680 shares during the last quarter. Global X Management Co. LLC raised its position in Regeneron Pharmaceuticals by 43.8% in the second quarter. Global X Management Co. LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $592,000 after buying an additional 367 shares during the last quarter. HL Financial Services LLC bought a new position in Regeneron Pharmaceuticals during the second quarter valued at $669,000. Finally, Seven Bridges Advisors LLC raised its position in Regeneron Pharmaceuticals by 13.7% in the second quarter. Seven Bridges Advisors LLC now owns 1,250 shares of the biopharmaceutical company’s stock valued at $614,000 after buying an additional 151 shares during the last quarter. Institutional investors own 67.16% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up 0.85% on Friday, hitting $467.98. 549,722 shares of the company traded hands. The firm’s 50 day moving average price is $489.51 and its 200-day moving average price is $430.92. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The stock has a market capitalization of $49.62 billion, a price-to-earnings ratio of 46.95 and a beta of 1.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same quarter in the prior year, the firm posted $2.82 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.85 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/19/mengis-capital-management-inc-raises-position-in-regeneron-pharmaceuticals-inc-nasdaqregn-updated.html.

A number of equities analysts have weighed in on the stock. UBS AG set a $489.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 5th. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Leerink Swann reiterated an “outperform” rating and set a $580.00 target price (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $472.00 target price (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Finally, Robert W. Baird lowered shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price for the company. in a research report on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $495.59.

In related news, Chairman P Roy Vagelos sold 9,295 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $458.14, for a total transaction of $4,258,411.30. Following the sale, the chairman now owns 414,156 shares in the company, valued at approximately $189,741,429.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Sanofi bought 136,050 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, June 2nd. The stock was acquired at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The disclosure for this purchase can be found here. Insiders have sold a total of 84,404 shares of company stock worth $40,303,792 in the last 90 days. 10.40% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.